Introduction
The question of whether Goods and Services Tax (GST) can be imposed on medicines administered to patients admitted in hospitals has resurfaced in the Indian legal arena. A petition before the Delhi High Court seeks clarity on the taxability of drugs supplied during inpatient treatment, a matter that touches on fiscal policy, patient affordability, and the operational costs of hospitals. As the nation grapples with balancing revenue generation against public health imperatives, the court’s ruling could set a precedent that influences the entire healthcare ecosystem. This article unpacks the legal framework, the arguments presented, and the possible ramifications for stakeholders across the board.
Legal backdrop of GST on medical supplies
Since the introduction of GST in 2017, the tax structure for medicines has been a patchwork of exemptions and reduced rates. Essential drugs listed under the National List of Essential Medicines (NLEM) enjoy a 0% GST rate, while other pharmaceutical products are taxed at 5% or 12% depending on their classification. The Central Board of Indirect Taxes and Customs (CBIC) has periodically issued notifications clarifying these categories, yet ambiguity remains when medicines are supplied as part of a bundled hospital service.
The Delhi High Court petition and arguments
The petition, filed by a consortium of private hospitals, argues that medicines administered to in‑patients should be treated as a component of the overall medical service, which is largely exempt from GST under Section 5(2)(e) of the GST Act. The respondents, representing the tax department, contend that the supply of drugs is a distinct taxable event, warranting the applicable GST rate. Both sides have submitted extensive evidence, including hospital billing practices, patient cost analyses, and precedents from other jurisdictions where inpatient drug supply is exempt.
Implications for hospitals and patients
If the court upholds the taxability of inpatient medicines, hospitals could face increased billing complexity and higher operational costs, potentially passing the burden onto patients. Conversely, an exemption would reinforce the principle that critical healthcare services remain financially accessible. Key impacts include:
- Pricing transparency: Hospitals would need to itemise GST on drug invoices.
- Insurance claims: Insurers may need to adjust reimbursement models to account for tax components.
- Public health: Higher out‑of‑pocket expenses could deter patients from seeking timely care.
Potential outcomes and broader impact
The judgment could trigger a cascade of policy revisions. A ruling favoring exemption may prompt the CBIC to issue a dedicated notification clarifying the status of inpatient drug supply, while a taxability verdict could lead to a revision of hospital billing software and training. Moreover, the decision may influence other state high courts handling similar disputes, gradually shaping a uniform national stance on the issue.
| Medicine category | GST rate (as of 20 Dec 2025) |
|---|---|
| Essential medicines (NLEM) | 0% |
| Non‑essential medicines (generic) | 5% |
| Specialty & biologics | 12% |
Conclusion
The Delhi High Court’s examination of GST on inpatient medicines sits at the intersection of tax law and public health. A clear, definitive ruling will either streamline hospital billing and safeguard patient affordability or introduce a new tax layer that could strain both providers and consumers. Stakeholders—from policymakers to clinicians—must prepare for either scenario, ensuring that the ultimate outcome aligns with India’s broader goal of delivering affordable, high‑quality healthcare.
Image by: MART PRODUCTION
https://www.pexels.com/@mart-production
